Of note, while increasing evidence points to ssDNA gaps as the initial DNA lesion that sensitizes cancer cells to PARPi, work from the Jasin laboratory has recently suggested that, at least in a BRCA2-mutant setting, loss of HR is the ‘ultimate’ cause of sensitization to PARPi [43]. The gene discussed is BRCA2; the disease is cancer.